Brokerages expect Natus Medical Inc (NASDAQ:BABY) to report $138.04 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Natus Medical’s earnings, with the lowest sales estimate coming in at $136.30 million and the highest estimate coming in at $139.43 million. Natus Medical posted sales of $131.44 million in the same quarter last year, which would suggest a positive year over year growth rate of 5%. The company is scheduled to report its next quarterly earnings results on Wednesday, February 6th.
On average, analysts expect that Natus Medical will report full year sales of $530.21 million for the current year, with estimates ranging from $529.00 million to $531.54 million. For the next year, analysts expect that the company will post sales of $547.80 million, with estimates ranging from $540.70 million to $557.79 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Natus Medical.
Natus Medical (NASDAQ:BABY) last released its quarterly earnings results on Wednesday, October 24th. The medical equipment provider reported $0.40 earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.02). Natus Medical had a positive return on equity of 11.34% and a negative net margin of 3.53%. The business had revenue of $130.60 million during the quarter, compared to analyst estimates of $132.92 million. During the same period in the previous year, the company posted $0.40 EPS. The business’s revenue for the quarter was up 6.5% compared to the same quarter last year.
BABY stock opened at $30.00 on Thursday. The company has a quick ratio of 2.31, a current ratio of 3.21 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $990.49 million, a PE ratio of 20.69 and a beta of 0.59. Natus Medical has a 1 year low of $27.69 and a 1 year high of $43.60.
In other Natus Medical news, Director Ken Ludlum sold 8,000 shares of the company’s stock in a transaction on Thursday, August 2nd. The stock was sold at an average price of $36.89, for a total transaction of $295,120.00. Following the transaction, the director now directly owns 98,957 shares in the company, valued at $3,650,523.73. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jonathan Kennedy sold 47,600 shares of the company’s stock in a transaction on Thursday, August 30th. The stock was sold at an average price of $36.85, for a total value of $1,754,060.00. Following the transaction, the insider now owns 161,628 shares in the company, valued at $5,955,991.80. The disclosure for this sale can be found here. Corporate insiders own 5.50% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Sei Investments Co. raised its stake in shares of Natus Medical by 46.3% in the second quarter. Sei Investments Co. now owns 4,669 shares of the medical equipment provider’s stock valued at $161,000 after acquiring an additional 1,478 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Natus Medical by 1,010.8% in the second quarter. Tower Research Capital LLC TRC now owns 5,132 shares of the medical equipment provider’s stock valued at $177,000 after acquiring an additional 4,670 shares in the last quarter. Xact Kapitalforvaltning AB acquired a new stake in shares of Natus Medical in the second quarter valued at $201,000. Penn Davis Mcfarland Inc. acquired a new stake in shares of Natus Medical in the second quarter valued at $224,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Natus Medical in the second quarter valued at $244,000. Institutional investors own 96.07% of the company’s stock.
About Natus Medical
Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Further Reading: Market Capitalization – What it Means for Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.